2 September 2020 – Walder Wyss advises BioVersys AG, Basel, a biotech company focusing on research and development of small molecules which switch off drug resistance against antibiotics, on its Series B Financing Round. The financing round amounts to CHF 19 mio. and was subscribed by existing shareholders as well as new investors.

Walder Wyss advised BioVersys AG in connection with this transaction. The team was led by Alexander Gutmans (Partner, Transaction/M&A & Venture Capital) and Robert von Rosen (Partner, Transaction/M&A & Venture Capital) and included Ayesha Curmally (Partner, Notary Services), Jessica Aeschbach Flórez (Senior Associate, Transaction/M&A) and Karina Tschon (Associate Transaction/M&A).